ADC Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced its participation in two major investor conferences this September. The company will be represented by CEO Ameet Mallik at both events:

1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring a virtual fireside chat at 7:00 a.m. ET.

2. 10th Cantor Global Healthcare Conference 2024 on September 18, 2024, with a fireside chat scheduled from 11:30-12:00 p.m. ET.

Live webcasts of both presentations will be accessible through the company's website, with replays available for approximately 30 days after each event.

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September:

H.C. Wainwright 26^th Annual Global Investment Conference

Date: September 9, 2024
Presentation Time: 7:00 a.m. ET
Format: Virtual Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer

10^th Cantor Global Healthcare Conference 2024

Date: September 18, 2024
Presentation Time: 11:30-12:00 p.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer

Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit the Company website at adctherapeutics.com and follow us on LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

FAQ

What investor conferences will ADC Therapeutics (ADCT) attend in September 2024?

ADC Therapeutics will attend the H.C. Wainwright 26th Annual Global Investment Conference on September 9 and the 10th Cantor Global Healthcare Conference on September 18, 2024.

Who will represent ADC Therapeutics (ADCT) at the upcoming investor conferences?

Ameet Mallik, the Chief Executive Officer of ADC Therapeutics, will represent the company at both investor conferences in September 2024.

When is ADC Therapeutics' (ADCT) presentation at the H.C. Wainwright conference?

ADC Therapeutics' virtual fireside chat at the H.C. Wainwright conference is scheduled for September 9, 2024, at 7:00 a.m. ET.

What is the format of ADC Therapeutics' (ADCT) presentation at the Cantor Global Healthcare Conference?

ADC Therapeutics will participate in a fireside chat format at the Cantor Global Healthcare Conference on September 18, 2024, from 11:30-12:00 p.m. ET.

How can investors access ADC Therapeutics' (ADCT) conference presentations?

Investors can access live webcasts of the presentations through the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com.